Evidence map›Paper›PMID 28093642›Full record

ReviewEuropean journal of pediatrics2017

The ethical framework for performing research with rare inherited neurometabolic disease patients.

Viviana Giannuzzi, Hugo Devlieger, Lucia Margari, Viveca Lena Odlind, Lamis Ragab, Cinzia Maria Bellettato, Francesca D'Avanzo, Christina Lampe, Linda Cassis, Elisenda Cortès-Saladelafont and 9 more

Open access · hybridAbstract readReview
In one paragraph

Review in European journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Advanced therapy medicinal products: value judgement and ethical evaluation in health technology assessment.The European journal of health economics : HEPAC : health economics in prevention and care · 2020
    Article
  11. CDG Therapies: From Bench to Bedside.International journal of molecular sciences · 2018
    Review
  12. Ethical Considerations of Patient-Funded Research for Multiple Sclerosis Therapeutics.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 11 institutions in 9 countries.

Viviana GiannuzziFondazione Per la Ricerca Farmacologica Gianni Benzi Onlus, Via Abate Eustasio 30, 70010, Valenzano, BA, Italy. vg@benzifoundation.org.ORCID http://orcid.org/0000-0002-2534-6783
Hugo DevliegerDepartment of Development and Regeneration, University of Leuven, O&N IV Herestraat 49-box 805, 3000, Leuven, Belgium.
Lucia MargariDepartment of Basic Medical Sciences, Neuroscience and Sense Organs, "Aldo Moro" University of Bari, Piazza Giulio Cesare 11, 70124, Bari, Italy.
Viveca Lena OdlindDepartment of Obstetrics and Gynaecology, Uppsala Universitet, 751 85, Uppsala, SE, Sweden.
Lamis RagabCairo University, Al Orman Guiza, Giza, 12613, Egypt.
Cinzia Maria BellettatoBrains for Brain Foundation - onlus, Padova, Italy.
Francesca D'AvanzoBrains for Brain Foundation - onlus, Padova, Italy.
Christina LampeBrains for Brain Foundation - onlus, Padova, Italy.
Linda CassisNeurology, Gastroenterology Pathology and Clinical Biochemistry Departments, IRP-HSJD and CIBERER, Barcelona, Spain.
Elisenda Cortès-SaladelafontNeurology, Gastroenterology Pathology and Clinical Biochemistry Departments, IRP-HSJD and CIBERER, Barcelona, Spain.
Ángels Garcia CazorlaNeurology, Gastroenterology Pathology and Clinical Biochemistry Departments, IRP-HSJD and CIBERER, Barcelona, Spain.
Ivo BarićUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Ljerka Cvitanović-ŠojatSchool of Medicine, University of Zagreb, Zagreb, Croatia.
Ksenija FumićUniversity Hospital Centre Zagreb, Zagreb, Croatia.
Christine I DaliDepartment of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Franco BartoloniFondazione Per la Ricerca Farmacologica Gianni Benzi Onlus, Via Abate Eustasio 30, 70010, Valenzano, BA, Italy.
Fedele BonifaziFondazione Per la Ricerca Farmacologica Gianni Benzi Onlus, Via Abate Eustasio 30, 70010, Valenzano, BA, Italy.
Maurizio ScarpaBrains for Brain Foundation - onlus, Padova, Italy.
Adriana CeciFondazione Per la Ricerca Farmacologica Gianni Benzi Onlus, Via Abate Eustasio 30, 70010, Valenzano, BA, Italy.
Gianni Benzi Pharmacological Research Foundation · ITCentre for Biomedical Network Research on Rare Diseases · ESBrain Foundation · AUHelios Dr. Horst Schmidt Kliniken Wiesbaden · DEUniversity Hospital Centre Zagreb · HRCairo University · EGCopenhagen University Hospital · DKKU Leuven · BEUniversity of Bari Aldo Moro · ITUniversity of Zagreb · HRUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The need for performing clinical trials to develop well-studied and appropriate medicines for inherited neurometabolic disease patients faces ethical concerns mainly raising from four aspects: the diseases are rare; include young and very young patients; the neurological impairment may compromise the capability to provide 'consent'; and the genetic nature of the disease leads to further ethical implications. This work is intended to identify the ethical provisions applicable to clinical research involving these patients and to evaluate if these cover the ethical issues. Three searches have been performed on the European regulatory/legal framework, the literature and European Union-funded projects. The European legal framework offers a number of ethical provisions ruling the clinical research on paediatric, rare, inherited diseases with neurological symptoms. In the literature, relevant publications deal with informed consent, newborn genetic screenings, gene therapy and rights/interests of research participants. Additional information raised from European projects on sharing patients' data from different countries, the need to fill the gap of the regulatory framework and to improve information to stakeholders and patients/families.

conclusionSeveral recommendations and guidelines on ethical aspects are applicable to the inherited neurometabolic disease research in Europe, even though they suffer from the lack of a common ethical approach. What is Known: • When planning and conducting clinical trials, sponsors and researchers know that clinical trials are to be performed according to well-established ethical rules, and patients should be aware about their rights. • In the cases of paediatric patients, vulnerable patients unable to provide consent, genetic diseases' further rules apply. What is New: • This work discusses which ethical rules apply to ensure protection of patient's rights if all the above-mentioned features coexist. • This work shows available data and information on how these rules have been applied.

Indexed as

Metabolic DiseasesNervous System DiseasesRare DiseasesBiomedical ResearchChildClinical Trials as TopicEuropeEuropean UnionHumansInformed ConsentClinical researchEthicsGenetic diseasePaediatricRare

Identifiers

PMID28093642
PMCPMC5321701
OpenAlexW2574753589

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.